Cytoprotective Agent class drugs

2 results

  • dexrazoxane

    (Dexrazoxane for Injection)
    Almaject, Inc.
    Dexrazoxane for Injection is indicated to reduce cardiomyopathy incidence and severity in women with metastatic breast cancer receiving doxorubicin, after a cumulative dose of 300 mg/m², who will continue doxorubicin therapy for tumor control. It should not be used at the start of doxorubicin treatment.
    Medication Details
    Drug Interactions

  • dexrazoxane

    (Dexrazoxane for Injection)
    Almaject, Inc.
    Dexrazoxane for Injection is indicated to reduce the incidence and severity of cardiomyopathy in women with metastatic breast cancer receiving cumulative doxorubicin doses of 300 mg/m² or more, who will continue doxorubicin therapy for tumor control. It should not be used at the start of doxorubicin therapy.
    Medication Details
    Drug Interactions